Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma

Implications for therapy

M. Gupta, J. J. Han, M. Stenson, L. Wellik, Thomas Elmer Witzig

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) gene-expression profile has been shown to have a poorer prognosis compared with tumors with a germinal center B-cell type. ABC cell lines have constitutive activation of STAT3; however, the mechanisms regulating STAT3 signaling in lymphoma are unknown. In studies of class-I histone deacetylase (HDAC) expression, we found overexpression of HDAC3 in phospho STAT3-positive DLBCL and the HDAC3 was found to be complexed with STAT3. Inhibition of HDAC activity by panobinostat (LBH589) increased p300-mediated STAT3 Lys685 acetylation with increased nuclear export of STAT3 to the cytoplasm. HDAC inhibition abolished STAT3 Tyr705 phosphorylation with minimal effect on STAT3 Ser727 and JAK2 tyrosine activity. pSTAT3 Tyr705-positive DLBCLs were more sensitive to HDAC inhibition with LBH589 compared with pSTAT3 Tyr705-negative DLBCLs. This cytotoxicity was associated with downregulation of the direct STAT3 target Mcl-1. HDAC3 knockdown upregulated STAT3 Lys685 acetylation but prevented STAT3 Tyr705 phosphorylation and inhibited survival of pSTAT3-positive DLBCL cells. These studies provide the rationale for targeting STAT3-positive DLBCL tumors with HDAC inhibitors.

Original languageEnglish (US)
Pages (from-to)1356-1364
Number of pages9
JournalLeukemia
Volume26
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Histone Deacetylases
Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Acetylation
Phosphorylation
Histone Deacetylase Inhibitors
Germinal Center
Cell Nucleus Active Transport
Therapeutics
Transcriptome
Tyrosine
Lymphoma
Neoplasms
Cytoplasm
Down-Regulation
Cell Line
histone deacetylase 3
panobinostat

Keywords

  • HDAC3
  • LBH589
  • Lymphoma
  • Mcl-1
  • STAT3

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma : Implications for therapy. / Gupta, M.; Han, J. J.; Stenson, M.; Wellik, L.; Witzig, Thomas Elmer.

In: Leukemia, Vol. 26, No. 6, 06.2012, p. 1356-1364.

Research output: Contribution to journalArticle

Gupta, M. ; Han, J. J. ; Stenson, M. ; Wellik, L. ; Witzig, Thomas Elmer. / Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma : Implications for therapy. In: Leukemia. 2012 ; Vol. 26, No. 6. pp. 1356-1364.
@article{7bd117bff24b472582c7e7fb74ceb61d,
title = "Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: Implications for therapy",
abstract = "Diffuse large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) gene-expression profile has been shown to have a poorer prognosis compared with tumors with a germinal center B-cell type. ABC cell lines have constitutive activation of STAT3; however, the mechanisms regulating STAT3 signaling in lymphoma are unknown. In studies of class-I histone deacetylase (HDAC) expression, we found overexpression of HDAC3 in phospho STAT3-positive DLBCL and the HDAC3 was found to be complexed with STAT3. Inhibition of HDAC activity by panobinostat (LBH589) increased p300-mediated STAT3 Lys685 acetylation with increased nuclear export of STAT3 to the cytoplasm. HDAC inhibition abolished STAT3 Tyr705 phosphorylation with minimal effect on STAT3 Ser727 and JAK2 tyrosine activity. pSTAT3 Tyr705-positive DLBCLs were more sensitive to HDAC inhibition with LBH589 compared with pSTAT3 Tyr705-negative DLBCLs. This cytotoxicity was associated with downregulation of the direct STAT3 target Mcl-1. HDAC3 knockdown upregulated STAT3 Lys685 acetylation but prevented STAT3 Tyr705 phosphorylation and inhibited survival of pSTAT3-positive DLBCL cells. These studies provide the rationale for targeting STAT3-positive DLBCL tumors with HDAC inhibitors.",
keywords = "HDAC3, LBH589, Lymphoma, Mcl-1, STAT3",
author = "M. Gupta and Han, {J. J.} and M. Stenson and L. Wellik and Witzig, {Thomas Elmer}",
year = "2012",
month = "6",
doi = "10.1038/leu.2011.340",
language = "English (US)",
volume = "26",
pages = "1356--1364",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma

T2 - Implications for therapy

AU - Gupta, M.

AU - Han, J. J.

AU - Stenson, M.

AU - Wellik, L.

AU - Witzig, Thomas Elmer

PY - 2012/6

Y1 - 2012/6

N2 - Diffuse large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) gene-expression profile has been shown to have a poorer prognosis compared with tumors with a germinal center B-cell type. ABC cell lines have constitutive activation of STAT3; however, the mechanisms regulating STAT3 signaling in lymphoma are unknown. In studies of class-I histone deacetylase (HDAC) expression, we found overexpression of HDAC3 in phospho STAT3-positive DLBCL and the HDAC3 was found to be complexed with STAT3. Inhibition of HDAC activity by panobinostat (LBH589) increased p300-mediated STAT3 Lys685 acetylation with increased nuclear export of STAT3 to the cytoplasm. HDAC inhibition abolished STAT3 Tyr705 phosphorylation with minimal effect on STAT3 Ser727 and JAK2 tyrosine activity. pSTAT3 Tyr705-positive DLBCLs were more sensitive to HDAC inhibition with LBH589 compared with pSTAT3 Tyr705-negative DLBCLs. This cytotoxicity was associated with downregulation of the direct STAT3 target Mcl-1. HDAC3 knockdown upregulated STAT3 Lys685 acetylation but prevented STAT3 Tyr705 phosphorylation and inhibited survival of pSTAT3-positive DLBCL cells. These studies provide the rationale for targeting STAT3-positive DLBCL tumors with HDAC inhibitors.

AB - Diffuse large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) gene-expression profile has been shown to have a poorer prognosis compared with tumors with a germinal center B-cell type. ABC cell lines have constitutive activation of STAT3; however, the mechanisms regulating STAT3 signaling in lymphoma are unknown. In studies of class-I histone deacetylase (HDAC) expression, we found overexpression of HDAC3 in phospho STAT3-positive DLBCL and the HDAC3 was found to be complexed with STAT3. Inhibition of HDAC activity by panobinostat (LBH589) increased p300-mediated STAT3 Lys685 acetylation with increased nuclear export of STAT3 to the cytoplasm. HDAC inhibition abolished STAT3 Tyr705 phosphorylation with minimal effect on STAT3 Ser727 and JAK2 tyrosine activity. pSTAT3 Tyr705-positive DLBCLs were more sensitive to HDAC inhibition with LBH589 compared with pSTAT3 Tyr705-negative DLBCLs. This cytotoxicity was associated with downregulation of the direct STAT3 target Mcl-1. HDAC3 knockdown upregulated STAT3 Lys685 acetylation but prevented STAT3 Tyr705 phosphorylation and inhibited survival of pSTAT3-positive DLBCL cells. These studies provide the rationale for targeting STAT3-positive DLBCL tumors with HDAC inhibitors.

KW - HDAC3

KW - LBH589

KW - Lymphoma

KW - Mcl-1

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84862019471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862019471&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.340

DO - 10.1038/leu.2011.340

M3 - Article

VL - 26

SP - 1356

EP - 1364

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -